Status:
UNKNOWN
Selective Dose Escalation for Esophageal Cancer
Lead Sponsor:
The Oregon Clinic
Collaborating Sponsors:
Bristol-Myers Squibb
MedImmune LLC
Conditions:
Esophageal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This prospective study was designed to assess the outcomes (survival and failure patterns) of therapy for localized esophageal cancer with conventional dose radiation (RT; 50.4 Gy) with concurrent con...
Detailed Description
we prospectively enrolled patients with T1-4, N0-1, M0-1a esophageal carcinoma to receive paclitaxel 45 mg/m2 IV over 1 hour and carboplatin AUC 2 IV over 30 minutes on days 1, 8, 15, 22, 29 and 36. 5...
Eligibility Criteria
Inclusion
- T1-4, N0-1, M0-1a esophageal carcinoma
Exclusion
- distant metastases
Key Trial Info
Start Date :
July 1 2000
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00139633
Start Date
July 1 2000
End Date
June 1 2005
Last Update
August 31 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Oregon Clinic
Portland, Oregon, United States, 97213